Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Camostat mesylate (HB3595)
Description:Serine protease inhibitor. Inhibits TMPRSS2 and partially blocks SARS-Cov2 entry in vitro.
Purity:>98%
Cycloheximide (HB2904)
Description:Eukaryotic protein synthesis inhibitor. Apoptosis inducer.
Purity:>95%
Cyclosporin A (HB0220)
Description:Potent calcineurin inhibitor. Inhibits MPTP opening.
Purity:>99%
Daunorubicin hydrochloride (HB4376)
Description:RNA and DNA synthesis inhibitor. Antibiotic.
Purity:>98%
Dexamethasone (HB2521)
Description:Anti-inflammatory synthetic glucocorticoid. Induces hMSC differentiation. Apoptosis inducer.
Purity:>98%
Dexamethasone (water-soluble) (HB6020)
Description:Synthetic glucocorticoid with potent anti-inflammatory actions. Induces hMSC differentiation. Apoptosis inducer. Water soluble and suitable for cell culture.Â
Purity:>98%